The pathogenesis of coronary artery calcification and its role in atherogenesis has not been completely understood but is a new focus of interest in experimental and clinical research. Various bioactive substances, including hormones, have been implicated in the process of arterial calcification. This review considers the relationship between coronary artery calcification and hormones. These hormones may become therapeutic targets for the prevention of arterial calcification.
FitzpatrickLASeversonAEdwardsWDIngramRT. Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis. J Clin Invest. 1994;94(4):1597–604.
2.
HeneinMYOwenA. Statins moderate coronary stenoses but not coronary calcification: results from meta-analyses. Int J Cardiol. 2010[Epub ahead of print] PMID: 20843566.
3.
DohertyTMDetranoRCMautnerSLMaunterGCShavelleRM. Coronary calcium: the good, the bad and the uncertain. Am Heart J. 1999;137(5):774–776.
4.
DohertyTMDetranoRC. Coronary arterial calcification as an active process: a new perspective on an old problem. Calcif Tissue Int. 1994;54(3):224–230.
5.
GuzmanRJ. Clinical, cellular, and molecular aspects of arterial calcification. J Vasc Surg. 2007;45 Suppl A:A57–A63.
6.
WatsonKE. Pathophysiology of coronary calcification. J Cardiovasc Risk. 2000;7(2):93–97.
7.
DemerLLTintutY. Vascular calcification: pathobiology of a multifaceted disease. Circulation. 2008;117(22):2938–2948.
GrodsteinFStampferM. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis. 1995;38(3):199–210.
10.
MendelsohnMEKarasRH. The protective effects of oestrogen on the cardiovascular system. N Engl J Med. 1999;340(23):1801–1811.
RossouwJEAndersonGLPrenticeRL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative Randomized Controlled Trial. JAMA. 2002;288(3):321–333.
13.
HulleySFurbergCBarrett-ConnorE. No cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up. JAMA. 2002;288(1):58–66.
14.
McLaughlinVVHoffJARichS. Relation between hormone replacement therapy in women and coronary artery disease estimated by electron beam tomography. Am Heart J. 1997;134(6):1115–1119.
15.
ChristianRCHarringtonSEdwardsWDObergALFitzpatrickLA. Estrogen status correlates with the calcium content of coronary atherosclerotic plaques in women. J Clin Endocrinol Metab. 2002;87(3):1062–1067.
16.
MansonJE
and WHI and WHI-CACS Investigators. Estrogen therapy and coronary artery calcification. N Engl J Med. 2007;356(25):2591–2602.
17.
AkhrassFEvansATWangY. Hormone replacement therapy is associated with less coronary atherosclerosis in postmenopausal women. J Clin Endocrinol Metab. 2003;88(12):5611–5614.
18.
Barrett-ConnorELaughlinGA. Hormone therapy and coronary artery calcification in asymptomatic postmenopausal women: the Rancho Bernardo Study. Menopause. 2005;12(1):40–48.
19.
AlexandersenPTankoLBBaggerYZQinGChristiansenC. The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric. 2006;9(2):108–118.
ShaharEBrukeGLCushmanMHeckbertSROuyangPSzkloM. Post menopausal hormones and measures of subclinical atherosclerosis: The Multi-Ethnic Study of Atherosclerosis. Prev Med. 2008;47(1):38–45.
22.
BudoffMJChenGPHunterCJ. Effects of hormone replacement on progression of coronary calcium as measured by electron beam tomography. J Womens Health. 2005;14(5):410–417.
23.
SchistermanEFGallagherAMBairey MerzCN. The association of hormone replacement therapy and coronary calcium as determined by electron beam tomography. J Womens Health Gend Based Med. 2002;11(7):631–638.
24.
OuyangPVaidyaDDobsA. Sex hormones levels and subclinical atherosclerosis in postmenopausal women: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2009;204(1):255–261.
25.
MalkinCJPughPJMorrisPDAsifSJonesTHChannerKS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010;96(22):1821–1825.
26.
HaddadRMKennedyCCCaplesSM. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomised placebo-controlled trials. Mayo Clin Proc. 2007;82(1):29–39.
27.
McRobbLHandelsmanDJHeatherAK. Androgen-induced progression of arterial calcification in apolipoprotein E-null mice is uncoupled from plaque growth and lipid levels. Endocrinology. 2009;150(2):841–848.
28.
MarxSJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med. 2000;343(25):1863–1875.
29.
YuNDonnanPTFlynnRWV. Increased mortality and morbidity in mild primary hyperparathyroid patients. Clinical Endocrinology. 2010;73(1):30–34.
30.
AradYSpadaroLARothM. Serum concentration of calcium, 1,25 vitamin D and parathyroid hormone are not correlated with coronary calcifications. An electron beam tomography study. Coron Artery Dis. 1998;9(8):513–518.
31.
StreetenEAMunirKHinesS. Coronary artery calcification in patients with primary hyperparathyroidism in comparison with control subjects from the multi-ethnic study of atherosclerosis. Endocr Pract. 2008;14(2):155–161.
32.
KepezAHarmanciAHazirolanT. Evaluation of subclinical coronary atherosclerosis in mild asymptomatic primary hyperparathyroidism patients. Int J Cardiovasc Imaging. 2009;25(2):187–193.
33.
HernandesFRBarretoFCRochaLADrabeSACanzianiMECarvalhoAB. Evaluation of the role of severe hyperparathyroidism on coronary artery calcification in dialysis patients. Clin Nephrol. 2007;67(2):89–95.
34.
BogazziFBattollaLSpinelliC. Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab. 2007;92(11):4271–4277.
35.
HerrmannBLSeveringMSchmermundA. Impact of disease duration on coronary calcification in patients with acromegaly. Exp Clin endocrinol Diab. 2009;117(8):417–422.
36.
KojimaMHosodaHDateYNakazatoMMatsuoHKangawaK. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656–660.
37.
LiGZJiangWZhaoJ. Ghrelin blunted vascular calcification in vivo and in vitro rats. Regul Pept. 2005;129(1-3):167–76.
38.
PfohlMAthanasiadisAKochM. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is associated with coronary artery plaque calcification as assessed by intravascular ultrasound. J Am Coll Cardiol. 1998;31(5):987–991.
39.
MattuRKNeedhamEWGaltonDJFrangosEClarkAJCaulfiedM. A DNA variant at the angiotensin-converting enzyme gene locus associates with coronary artery disease in the Caerphilly Heart Study. Circulation. 1995;91(2):270–274.
40.
NsengimanaJBarrettJH. Renin-angiotensin system genes and coronary artery calcification. Future Cardiol. 2007;3(6):587–590.
41.
OeiHHSayed-TabatabaeiFAHofmanAOudkerkMVan DuijinCMWittemanJC. The association between angiotensin-converting enzyme gene polymorphism and coronary calcification. The Rotterdam Coronary Calcification Study. Atherosclerosis. 2005;182(1):169–73.
42.
PischonTRimmE. Adiponectin: a promising marker for cardiovascular disease. Clin Chem. 2006;52(5):797–799.
43.
OhDKGiaraldiTHenryRR. Adiponectin in health and disease. Diabetes Obes Metab. 2007;9(3):282–289.
YamauchiTKamonJWakiH. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipatrophy and obesity. Nat Med. 2001;7(8):941–946.
47.
LawlorDADavey SmithGEbrahimSThompsonCSattarN. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab. 2005;90(10):5677–5683.
48.
SchulzeMBShaiIRimmEBLiTRifaiNHuFB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes. 2005;54(2):534–539.
49.
PischonTGirmanCJHotamisligilGSRifaiNHuFBRimmEB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291(14):1730–1737.
50.
KumadaMKiharaSSumitsujiS. Association of hypoadiponectinemia with coronary disease in men. Arterioscler Thromb Vasc Biol. 2003;23(1):85–89.
51.
OkamotoYKiharaSOuchiN. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002;106(22):2767–2770.
52.
MarsoSPMehtaSKFrutkinAHouseJAMcCraryJRKulkarniKR. Low adiponectin levels are associated with atherogenic dyslipidemia and lipid-rich plaque in nondiabetic coronary arteries. Diabetes Care. 2008;31(5):989–994.
53.
GreifMBeckerAvon ZieglerF. Pericardial adipose tissue determined by dual source CT is a risk factor for coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29(5):781–786.
QasimAMehtaNNTadesseMG. Adipokines, insulin resistance and coronary artery calcification. J Am Coll Cardiol. 2008;52(3):231–236.
56.
BroedlUCLebherzCLehrkeM. Low adiponectin levels are an independent predictor of mixed and non-calcified coronary atherosclerotic plaques. PLoS One. 2009;4(3):e4733.
57.
ChungCPLongAGSolusJF. Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus. 2009;18(9):799–806.
58.
RhoYHChungCPSolusJF. Adipocytokines, insulin, and coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 2010;62(5):1259–1264.
59.
BeltowskiJ. Leptin and atherosclerosis. Atherosclerosis. 2006;189(1):47–60.
60.
WallaceAMMcMahonADPackardCJ. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001;104(25):3052–3056.
61.
PoulakouMVParaskevasKIWilsonMR. Apolipoprotein J and leptin levels in patients with coronary heart disease. In Vivo. 2008;22(4):537–542.
62.
IribarrenCHussonGGoAS. Plasma leptin levels and coronary artery calcification in older adults. J Clin Endocrinol Metab. 2007;92(2):729–732.
63.
ReillyMPIqbalNSchuttaM. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab. 2004;89(8):3872–3878.
64.
WolkRBeggerPLennonRJBrilakisESJohnsonBDSomersVK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol. 2004;44(9):1819–1824.
65.
ZeadinMButcherMWerstuckGKhanMYeeCKShaughnessySG. Effect of leptin on vascular calcification in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2009;29(12):2069–2075.
66.
ReillyMPLehrkeMWolfeMLRohatgiALazarMARaderDJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005;111(7):932–939.
67.
WeikertCWestphalSBergerK. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab. 2008;93(7):2647–2653.
68.
FilippatosTDRandevaHSDerdemezisCSElisafMSMikhailidisDP. VISFATIN/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol. 2010[Epub ahead of print].
69.
Saddi-RosaPOliveiraCSGiuffridaFReisAF. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr. 2010;2:21.
70.
UzÖKardeşoğluEYiginerÖ. The relationship between coronary calcification and metabolic markers of osteopontin, fetuin-A and visfatin. Turk Kardiyol Dern Ars. 2009;37(6):397–402.
71.
Van CampenhourtAGolledgeJ. Osteoprotegerin. Vascular calcification and atherosclerosis. Atherosclerosis. 2009;204(2):321–329.
72.
SimonetWSLaceyDLDustanCR. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–19.
73.
HofbauerLCHeufelderAE. The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum. 2001;44(2):253–259.
74.
AshleyDTO’ SullivanEPDavenportC. Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects. Metabolism. 2010[Epub ahead of print] Pubmed PMID: 21087777.
75.
KiechlSSchettGWenningG. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109(18):2175–2180.
76.
VenurajuSMYerramasuACorderRLahiriA. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol. 2010;55(19):2049–2061.
77.
AvignonASultanAPiotC. Osteoprotegerin: a novel of independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care. 2007;30(11):2934–2939.
78.
UelandTJemtlandRGodangK. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol. 2004;44(10):1970–1976.
79.
OmlandTUelandTJanssonAM. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol. 2008;51(6):627–633.
80.
BrownerWSLuiLYCummingsSR. Associations of serum ostreoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001;86(2):631–637.
81.
MoronySTintutYCattletRC. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr (−/−) Mice. Circulation. 2008;117(3):411–420.
82.
MesquitaMDemulderADamryN. Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease. Clin Chem Lab Med. 2009;47(3):339–346.
83.
KurnatowskaIGrzelakPKaczmarskaMStefańczykLNowickiM. Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients. Nephron Clin Pract. 2010;117(4):c297–c304.
84.
MikamiSHamanoTFujiiN. Serum osteoprotegerin as a screening tool for coronary artery calcification score in diabetic pre-dialysis patients. Hypertens Res. 2008;31(6):1163–1170.
85.
BarretoDVBarretoFCCarvalhoAB. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int. 2005;67(4):1576–1582.
86.
AnandDVLahiriALimEHopkinsDCorderR. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol. 2006;47(9):1850–1857.
87.
KwonHMHongBKKangTS. Expression of osteopontin in calcified coronary atherosclerotic plaques. J Korean Med Sci. 2000;15(5):485–493.
88.
O’BrienERGarvinMRStewartDK. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb. 1994;14(10):1648–1656.
89.
BoskeyAlMarescaMUllrichWDotySBButlerWTPrinceCW. Osteopontin-hydroxyapatite interactions in vitro: inhibition of hydroxyapatite formation and growth in a gelatin-gel. Bone Miner. 1993;22(2):147–159.
90.
WadaTMcKeeMDSteitzSGiachelliCM. Calcification of vascular smmoth cell cultures: inhibition by osteopontin. Circ Res. 1999;84(2):166–178.
91.
LiGChenYFKelpkeSSOparilSThompsonJA. Estrogen attenuates integrin-beta (3)-dependent adventitial fibroblast migration after inhibition of osteopontin production in vascular smooth muscle cells. Circulation. 2000;101(25):2949–55.
92.
AryanMKepezAAtalarE. Association of plasma osteopontin levels with coronary calcification evaluated by tomographic coronary calcium scoring. J Bone Miner Metab. 2009;27(5):591–597.
93.
OhmoriRMomiyamaYTaniguchiH. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis. 2003;170(2):333–337.
94.
SchurginSRichSMazzoneT. Increased prevalence of significant coronary artery calcification in patients with diabetes. Diabetes Care. 2001;24(2):335–338.
95.
DabeleaSKinneyGSnell-BergeonJK. Effect of type 1diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes. 2003;52(11):2833–2839.
96.
TanakaMFukuiMTomiyasuK. U-shaped relationship between insulin level and coronary artery calcification (CAC). J Atheroscler Thromb. 2010;17(10):1033–1040.
97.
ReavenGM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–1607.
98.
KilpatrickESRigbyASAtkinSL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial. Diabetes Care. 2007;30(3):707–712.
99.
AradYNewsteinDCadetFRothMGuerciAD. Association of multiple risk factors and insulin resistance with increased prevalence of asymptomatic coronary artery disease by an electron-beam computed tomographic study. Arterioscler Thromb Vasc Biol. 2001;21(12):2051–2058.
100.
RodriguesTCBiavattiKAlmeidaFKGrossJL. Coronary artery calcification is associated with insulin resistance index in patients with type 1 diabetes. Braz J Med Biol Res. 2010;43(11):1084–1087.
101.
ElkelesRSGodslandIFFeherMD. Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. Eur Heart J. 2008;29(18):2244–2251.
102.
Maurovich-HorvatPMóriTKerecsenG. Assessment of coronary artery calcification using dual-source computed tomography in adult asymptomatic patients with type 1 diabetes mellitus. Med Sci Monit. 2010;16(7):MT59–MT64.
103.
LeeKKFortmannSPFairJM. Insulin resistance independently predicts the progression of coronary artery calcification. Am Heart J. 2009;157(5):939–945.
104.
KobayashiSOkaMMaesatoK. Coronary artery calcification, ADMA, and insulin resistance in CKD patients. Clin J Am Soc Nephrol. 2008;3(5):1289–1295.
105.
SchauerIESnell-BergeonJKBergmanBC. Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: the CACTI study. Diabetes2010[Epub ahead of print] PubMed PMID: 20978091.
106.
RennenbergRJSchurgersLJKroonAAStehouwerCD. Arterial calcifications. J Cell Mol Med J. 2010;14(9):2203–2210.
107.
KirkpanturAAltunBHazirolanT. Association among serum fetuin-A level, coronary artery calcification, and bone mineral densitometry in maintenance hemodialysis patients. Artif Organs. 2009;33(10):844–854.
108.
LorantDPGrujicicMHoebausC. Fetuin-A levels are increased in patients with type 2 diabetes and peripheral arterial disease. Diabetes Care. 2010[Epub ahead of print] PMID: 20929991.
109.
SulimanMEGarcía-LópezEAnderstamBLindholmBStenvinkelP. Vascular calcification inhibitors in relation to cardiovascular disease with special emphasis on fetuin-A in chronic kidney disease. Adv Clin Chem. 2008;46:217–262.
110.
WestenfeldRSchäferCKrügerT. Fetuin-A protects against atherosclerotic calcification in CKD. J Am Soc Nephrol. 2009;20(6):1264–1274.
111.
ZhangBShiWHeCSLiangXLLiuSXLiangYZ. [Low serum fetuin A is a risk factor of coronary artery calcification in patients starting hemodialysis]. [Article in Chinese] Nan Fang Yi Ke Da Xue Xue Bao. 2010;30(3):1002–4.
112.
MoriKIkariYJonoS. Fetuin-A is associated with calcified coronary artery disease. Coron Artery Dis. 2010;21(5):281–285.
113.
MehrotraRWestenfeldRChristensonP. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int. 2005;67(3):1070–1077.
114.
JungHHKimSWHanH. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant. 2006;21(7):1915–1920.
115.
GreenlandPLabreeLAzenSPDohertyTMDetranoRC. Coronary calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291(2):210–215.
116.
ShawLJRaggiPSchistermanEBermanDSCallisterTQ. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology. 2003;228(3):826–833.
117.
KondosGTHoffJASevrukovA. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation. 2003;107(20):2571–2576.
118.
RumbergerJABrundageBHRaderDJKondosG. Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc. 1999;74(3):243–252.
119.
BudoffMJRaggiP. Coronary artery disease progression assessed by electron beam computed tomography. Am J Cardiol. 2001;88(2A):46E–50E.
120.
KarsentyG. The complexities of skeletal biology. Nature. 2003;423(6937):316–318.
